Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 1.00 |
| ▸ | CA9 | Q16790 | 5/20 | 1.00 |
| ▸ | CA1 | P00915 | 4/20 | 1.00 |
| ▸ | CA7 | P43166 | 2/20 | 1.00 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.80 |
| ▸ | HPGD | P15428 | 5/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.80 |
| ▸ | CASP1 | P29466 | 4/20 | 0.80 |
| ▸ | CASP7 | P55210 | 4/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.80 |
| ▸ | GAA | P10253 | 3/20 | 0.78 |
| ▸ | GLA | P06280 | 2/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.78 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.78 |
| ▸ | STAT6 | P42226 | 1/20 | 0.78 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.77 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17838079 | 1.00 | CA12 (1.00) | CA12CA9CA1CA7CA13 | |
| Scopolin SCHEMBL1674804 | 1.00 | CA12 (1.00) | CA12CA9CA1CA7CA13 | |
| Scopolin SCHEMBL6260522 | 1.00 | CA12 (1.00) | CA12CA9CA1CA7CA13 | |
| Esculin SCHEMBL9754358 | 0.90 | HPGD (0.88) | CA12CA9CA1CA7CA13 | |
| SCHEMBL15745927 | 0.89 | CA12 (0.80) | CA12CA9CA1CA7CA13 | |
| Daphnorin SCHEMBL30616024 | 0.87 | TDP1 (1.00) | CA12CA9CA1CA7CA13 | |
| Esculin SCHEMBL2893 | 0.87 | ALDH1A1 (1.00) | CA12CA9CA1CA7CA13 | |
| Esculin SCHEMBL19756246 | 0.87 | ALDH1A1 (1.00) | CA12CA9CA1CA7CA13 | |
| Esculin SCHEMBL8183298 | 0.87 | ALDH1A1 (1.00) | CA12CA9CA1CA7CA13 | |
| Esculin SCHEMBL8035285 | 0.87 | ALDH1A1 (1.00) | CA12CA9CA1CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015081199-A1 | COMPOSITIONS AND METHODS FOR TREATING HERPESVIRUS INFECTION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-06-04 | — | — | WO | claimed |
| US-10226477-B2 | Composition for preventing, improving or treating postmenopausal osteoporosis comprising scopolin | DONG WOO DANG CO., LTD (KR) | 2019-03-12 | — | — | US | disclosed |
| US-20170252363-A1 | COMPOSITION FOR PREVENTING, IMPROVING OR TREATING POSTMENOPAUSAL OSTEOPOROSIS COMPRISING SCOPOLIN | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2017-09-07 | — | — | US | disclosed |
| WO-2015081199-A1 | COMPOSITIONS AND METHODS FOR TREATING HERPESVIRUS INFECTION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-06-04 | — | — | WO | disclosed |
| US-8828954-B2 | Use for scopolin and derivatives thereof | YONSEI UNIVERSITY TECHNOLOGY HOLDINGS, INC. (KR) | 2014-09-09 | — | — | US | disclosed |
| US-8828954-B2 | Use for scopolin and derivatives thereof | YONSEI UNIVERSITY TECHNOLOGY HOLDINGS, INC. (KR) | 2014-09-09 | — | — | US | disclosed |
| US-20120322754-A1 | NOVEL USE FOR SCOPOLIN AND DERIVATIVES THEREOF | YONSEI UNIVERSITY TECHNOLOGY HOLDINGS, INC (KR) | 2012-12-20 | — | — | US | disclosed |
| US-20120322754-A1 | NOVEL USE FOR SCOPOLIN AND DERIVATIVES THEREOF | YONSEI UNIVERSITY TECHNOLOGY HOLDINGS, INC (KR) | 2012-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322754-A1 | NOVEL USE FOR SCOPOLIN AND DERIVATIVES THEREOF | FABP1, FABP4, CPT1A | CA12 3212/4885CA9 2621/4885CA1 2680/4885 |
| US-20170252363-A1 | COMPOSITION FOR PREVENTING, IMPROVING OR TREATING POSTMENOPAUSAL OSTEOPOROSIS COMPRISING SCOPOLIN | SOST, SHBG, CHRM2 | CA12 475/4885CA9 886/4885CA1 213/4885 |
| US-10226477-B2 | Composition for preventing, improving or treating postmenopausal osteoporosis comprising scopolin | SOST, SHBG, CHRM2 | CA12 475/4885CA9 886/4885CA1 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.